GSK publishes pipeline assets and clinical trials presentation
GSK•GSK published its Q3 2026 pipeline report, which lists 62 potential vaccines and medicines, including 21 in Phase III or registration. The update includes two Phase III advances, positive registrational data for Jideytro, and the start of efimosfermin alfa Phase III trials.
1. Pipeline updates
GSK’s Q3 2026 pipeline includes 62 potential vaccines and medicines, with 21 in Phase III or registration. Felcorekibart for asthma advanced to Phase III, and seasonal flu vaccine GSK4382276 progressed to Phase III or registration. Jideytro delivered positive registrational data in treatment-naive patients with ROS1-positive non-small cell lung cancer. Efimosfermin alfa Phase III trials in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis started in Q3 2026.
